Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study.

Humans Non-alcoholic Fatty Liver Disease / complications Carcinoma, Hepatocellular / pathology Cohort Studies Retrospective Studies Liver Neoplasms / pathology Liver / pathology Liver Cirrhosis / pathology Biopsy
Asian Cirrhosis Fibrosis Liver-related Mortality

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
02 2023
Historique:
received: 21 10 2021
revised: 24 12 2021
accepted: 03 01 2022
pubmed: 21 1 2022
medline: 28 1 2023
entrez: 20 1 2022
Statut: ppublish

Résumé

There are no detailed reports of clinical outcomes in Asian patients with nonalcoholic fatty liver disease (NAFLD) who undergo liver biopsy. We aimed to investigate the clinical outcomes of a large cohort of Asian patients with biopsy-proven NAFLD and evaluate the specific effects of nonalcoholic steatohepatitis and fibrosis stage. This multicenter registry-based retrospective cohort study, called the CLIONE (Clinical Outcome Nonalcoholic Fatty Liver Disease) in Asia, included 1398 patients. The median follow-up period was 4.6 years (range, 0.3-21.6 years), representing a total of 8874 person-years of follow-up. During that time, 47 patients died, and 1 patient underwent orthotopic liver transplantation. The leading cause of death was nonhepatic cancer (n = 10). The leading causes of liver-related death were liver failure (n = 9), hepatocellular carcinoma (HCC) (n = 8), and cholangiocellular carcinoma (n = 4). During follow-up, 37 patients developed HCC, 31 developed cardiovascular disease, and 68 developed nonhepatic cancer (mainly breast, stomach, and colon/rectum). Among our cohort of patients with NAFLD, liver-specific mortality was 2.34/1000 person-years (95% confidence interval [CI], 1.52-3.58), overall mortality was 5.34/1000 person-years (95% CI, 4.02-7.08), and HCC incidence was 4.17/1000 person-years (95% CI, 3.02-5.75). Liver fibrosis was independently associated with liver-related events but not overall mortality. Liver-related mortality was the leading cause of mortality in Asian patients with biopsy-confirmed NAFLD. Although fibrosis stage was independently associated with liver-related events, it was not associated with overall mortality after adjusting for confounders, such as histologic features of steatohepatitis.

Sections du résumé

BACKGROUND & AIMS
There are no detailed reports of clinical outcomes in Asian patients with nonalcoholic fatty liver disease (NAFLD) who undergo liver biopsy. We aimed to investigate the clinical outcomes of a large cohort of Asian patients with biopsy-proven NAFLD and evaluate the specific effects of nonalcoholic steatohepatitis and fibrosis stage.
METHODS
This multicenter registry-based retrospective cohort study, called the CLIONE (Clinical Outcome Nonalcoholic Fatty Liver Disease) in Asia, included 1398 patients.
RESULTS
The median follow-up period was 4.6 years (range, 0.3-21.6 years), representing a total of 8874 person-years of follow-up. During that time, 47 patients died, and 1 patient underwent orthotopic liver transplantation. The leading cause of death was nonhepatic cancer (n = 10). The leading causes of liver-related death were liver failure (n = 9), hepatocellular carcinoma (HCC) (n = 8), and cholangiocellular carcinoma (n = 4). During follow-up, 37 patients developed HCC, 31 developed cardiovascular disease, and 68 developed nonhepatic cancer (mainly breast, stomach, and colon/rectum). Among our cohort of patients with NAFLD, liver-specific mortality was 2.34/1000 person-years (95% confidence interval [CI], 1.52-3.58), overall mortality was 5.34/1000 person-years (95% CI, 4.02-7.08), and HCC incidence was 4.17/1000 person-years (95% CI, 3.02-5.75). Liver fibrosis was independently associated with liver-related events but not overall mortality.
CONCLUSIONS
Liver-related mortality was the leading cause of mortality in Asian patients with biopsy-confirmed NAFLD. Although fibrosis stage was independently associated with liver-related events, it was not associated with overall mortality after adjusting for confounders, such as histologic features of steatohepatitis.

Identifiants

DOI: 10.1016/j.cgh.2022.01.002 PMID: 35051649
pubmed: 35051649
pii: S1542-3565(22)00008-8
doi: 10.1016/j.cgh.2022.01.002
pii:
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

370-379

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Hideki Fujii (H)

Departments of Premier Preventive Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan; Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan.

Michihiro Iwaki (M)

Division of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Hideki Hayashi (H)

Department of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu, Japan.

Hidenori Toyoda (H)

Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.

Satoshi Oeda (S)

Liver Center, Saga University Hospital, Saga, Japan; Department of Laboratory Medicine, Saga University Hospital, Saga, Japan.

Hideyuki Hyogo (H)

Department of Gastroenterology, JA Hiroshima Kouseiren General Hospital, Hatsukaichi, Hiroshima, Japan.

Miwa Kawanaka (M)

Department of General Internal Medicine 2, Kawasaki Medical Center, Kawasaki Medical School, Okayama, Japan.

Asahiro Morishita (A)

Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.

Kensuke Munekage (K)

Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi, Japan.

Kazuhito Kawata (K)

Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Shizuoka, Japan.

Sakura Yamamura (S)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.

Koji Sawada (K)

Liver Disease Care Unit, Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Asahikawa Medical University, Asahikawa, Japan; Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.

Tatsuji Maeshiro (T)

First Department of Internal Medicine, University of the Ryukyus Hospital, Okinawa, Japan.

Hiroshi Tobita (H)

Division of Hepatology, Shimane University Hospital, Shimane, Japan.

Yuichi Yoshida (Y)

Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Osaka, Japan.

Masafumi Naito (M)

Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Osaka, Japan.

Asuka Araki (A)

Division of Hepatology, Shimane University Hospital, Shimane, Japan.

Shingo Arakaki (S)

First Department of Internal Medicine, University of the Ryukyus Hospital, Okinawa, Japan.

Takumi Kawaguchi (T)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.

Hidenao Noritake (H)

Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Shizuoka, Japan.

Masafumi Ono (M)

Division of Innovative Medicine for Hepatobiliary & Pancreatology, Faculty of Medicine, Kagawa University, Kagawa, Japan.

Tsutomu Masaki (T)

Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.

Satoshi Yasuda (S)

Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.

Eiichi Tomita (E)

Department of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu, Japan.

Masato Yoneda (M)

Division of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Norifumi Kawada (N)

Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan.

Akihiro Tokushige (A)

Department of Cardiovascular Medicine and Hypertension, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Yoshihiro Kamada (Y)

Department of Advanced Metabolic Hepatology, Osaka University, Graduate School of Medicine, Osaka, Japan.

Hirokazu Takahashi (H)

Liver Center, Saga University Hospital, Saga, Japan.

Shinichiro Ueda (S)

Department of Clinical Pharmacology and Therapeutics, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.

Shinichi Aishima (S)

Department of Pathology and Microbiology, Faculty of Medicine, Saga University, Saga, Japan.

Yoshio Sumida (Y)

Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Aichi, Karimata, Japan. Electronic address: sumida19701106@yahoo.co.jp.

Atsushi Nakajima (A)

Division of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Takeshi Okanoue (T)

Hepatology Center, Saiseikai Suita Hospital, Suita, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Clinical Outcomes in Biopsy-Proven...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Stéatose hépatique › Stéatose hépatique non alcoolique › Clinical Outcomes in Biopsy-Proven...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Carcinome hépatocellulaire › Clinical Outcomes in Biopsy-Proven...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Clinical Outcomes in Biopsy-Proven...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Clinical Outcomes in Biopsy-Proven...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Clinical Outcomes in Biopsy-Proven...
questionsmedicales.fr › Système digestif › Foie › Clinical Outcomes in Biopsy-Proven...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Fibrose › Cirrhose du foie › Clinical Outcomes in Biopsy-Proven...
questionsmedicales.fr › Techniques d'investigation › Techniques cytologiques › Cytodiagnostic › Biopsie › Clinical Outcomes in Biopsy-Proven...